Download PDFPDF

Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address